Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Here, the authors show that neutralization of human sera from both BNT162b2 vaccine recipients and from convalescent COVID-19 patients is less efficient against SARS- CoV-2 variants B.1.1.7 and B.1.351 and negatively associated with patient age.
Guardado en:
Autores principales: | Timothy A. Bates, Hans C. Leier, Zoe L. Lyski, Savannah K. McBride, Felicity J. Coulter, Jules B. Weinstein, James R. Goodman, Zhengchun Lu, Sarah A. R. Siegel, Peter Sullivan, Matt Strnad, Amanda E. Brunton, David X. Lee, Andrew C. Adey, Benjamin N. Bimber, Brian J. O’Roak, Marcel E. Curlin, William B. Messer, Fikadu G. Tafesse |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bb8db59a951140a893c150893245d2b7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Esther Saiag, et al.
Publicado: (2021) -
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Nicola Silvestris
Publicado: (2021) -
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Yamato Nishiguchi, et al.
Publicado: (2021) -
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Akihiro Matsubara, et al.
Publicado: (2021) -
Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Toshiyuki Sumi, et al.
Publicado: (2021)